Engineering Stapled Peptide Inhibitors Reveals Design Principles for Targeting Talin-Induced Integrin Activation
- 1Fox Chase Cancer Center
Abstract
Talin-induced integrin activation is a central regulator of cell adhesion and signaling. Intracellular Targeting of this pathway remains to be challenging. Here, we report the structure-guided development of next-generation stapled peptidomimetics derived from the RIAM talin-binding site (TBS). Using biochemical, structural, and cellular analyses, we show that the second-generation S2-TBS enhances talin binding and inhibitory potency but exhibits reduced cell uptake due to an extended linker. Guided by these insights, we designed a minimized third-generation peptide, S3-TBS, which restores structural order, improves thermal stability and cell uptake, and retains strong talin binding. NMR and crystallographic analyses confirm conserved binding to specific interfaces in talin head and talin rod domains. Functionally, optimized peptides potently inhibit talin-mediated integrin interactions and suppress invadopodia-driven matrix degradation in cancer cells. These findings establish key principles for balancing affinity, conformational stability, and molecular size in the design of intracellular stapled peptide inhibitors.
Related
- Curved adhesions resist disruption by high-affinity αv integrin inhibitors
- Triple-helical ligands selectively targeting the closed αI domain of integrin α2β1
- Activation of α7 Nicotinic Acetylcholine Receptor Inhibits Neutrophil ex vivo Swarming and Pulmonary Recruitment in Inflamed Mice through an Integrin αMβ2-dependent Mechanism
- Receptor-proximal phosphoform organization precedes β2 integrin activation
- Attenuated β2 Integrin Expression in Neutrophils Alters Dendritic Cell Stimulation and T Cell Activation in Old Mice
BibTeX
@misc{gao2026engineering,
title = {{Engineering Stapled Peptide Inhibitors Reveals Design Principles for Targeting Talin-Induced Integrin Activation}},
author = {T. Gao and E. Belova and Y. Mori and W. H. Deni and H. Roder and B. Gligorijevic and J. Wu and K. Wang},
howpublished = {bioRxiv},
year = {2026},
month = may,
doi = {10.64898/2026.05.25.727761},
url = {https://www.biorxiv.org/content/10.64898/2026.05.25.727761v3},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Engineering Stapled Peptide Inhibitors Reveals Design Principles for Targeting Talin-Induced Integrin Activation
AU - T. Gao
AU - E. Belova
AU - Y. Mori
AU - W. H. Deni
AU - H. Roder
AU - B. Gligorijevic
AU - J. Wu
AU - K. Wang
PY - 2026
DA - 2026/05/25
PB - bioRxiv
DO - 10.64898/2026.05.25.727761
UR - https://www.biorxiv.org/content/10.64898/2026.05.25.727761v3
AB - Talin-induced integrin activation is a central regulator of cell adhesion and signaling. Intracellular Targeting of this pathway remains to be challenging. Here, we report the structure-guided development of next-generation stapled peptidomimetics derived from the RIAM talin-binding site (TBS). Using biochemical, structural, and cellular analyses, we show that the second-generation S2-TBS enhances talin binding and inhibitory potency but exhibits reduced cell uptake due to an extended linker. Guided by these insights, we designed a minimized third-generation peptide, S3-TBS, which restores structural order, improves thermal stability and cell uptake, and retains strong talin binding. NMR and crystallographic analyses confirm conserved binding to specific interfaces in talin head and talin rod domains. Functionally, optimized peptides potently inhibit talin-mediated integrin interactions and suppress invadopodia-driven matrix degradation in cancer cells. These findings establish key principles for balancing affinity, conformational stability, and molecular size in the design of intracellular stapled peptide inhibitors.
ER -